🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 2 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
13/03/2014 32,05 32,49 31,00 31,98 -0,47% 4,65% 353.200
12/03/2014 31,38 32,19 31,00 32,13 +1,61% 3,79% 243.600
11/03/2014 31,14 32,00 30,26 31,62 +1,84% 5,59% 170.800
10/03/2014 30,85 31,31 29,77 31,05 +0,16% 4,99% 209.600
07/03/2014 32,81 33,35 28,23 31,00 -7,13% 15,60% 616.000
06/03/2014 33,84 34,65 32,68 33,38 -1,33% 5,82% 233.200
05/03/2014 33,87 34,05 33,22 33,83 -0,09% 2,45% 186.800
04/03/2014 32,71 34,29 31,58 33,86 +4,57% 8,28% 202.800
03/03/2014 30,80 32,71 29,48 32,38 +3,25% 10,49% 356.800
28/02/2014 34,20 34,62 30,06 31,36 -7,68% 13,33% 469.700
27/02/2014 32,15 34,22 31,86 33,97 +5,01% 7,34% 214.700
26/02/2014 32,12 33,74 31,20 32,35 +0,43% 7,91% 230.100
25/02/2014 29,90 33,02 29,03 32,21 +7,65% 13,34% 262.000
24/02/2014 29,83 30,46 29,61 29,92 -0,13% 2,85% 176.000
21/02/2014 30,20 31,00 29,60 29,96 -0,96% 4,64% 394.000
20/02/2014 28,77 30,57 28,53 30,25 +5,95% 7,09% 454.100
19/02/2014 28,32 28,99 27,94 28,55 +0,42% 3,71% 143.400
18/02/2014 27,62 29,17 27,46 28,43 +6,80% 6,19% 293.500
14/02/2014 26,30 27,73 25,91 26,62 +2,27% 6,92% 188.700
13/02/2014 25,60 26,40 24,69 26,03 +3,58% 6,68% 2.178.400
12/02/2014 23,42 25,49 22,87 25,13 +7,03% 11,19% 103.400
11/02/2014 25,05 25,05 23,41 23,48 -6,16% 6,55% 111.800
10/02/2014 22,83 25,62 22,83 25,02 +9,93% 12,22% 93.500
07/02/2014 22,13 23,09 21,75 22,76 +3,36% 6,06% 89.400
06/02/2014 22,03 22,34 21,80 22,02 +0,50% 2,45% 198.400
05/02/2014 22,89 22,94 21,67 21,91 -4,74% 5,55% 174.000
04/02/2014 22,47 23,85 22,37 23,00 +3,14% 6,59% 149.500
03/02/2014 26,05 26,89 22,19 22,30 -14,46% 18,04% 139.700
31/01/2014 26,35 26,77 25,83 26,07 -2,83% 3,57% 153.100
30/01/2014 25,71 27,43 24,80 26,83 +4,36% 10,23% 464.900